Ductal Carcinoma in Situ

Article

A 57-year-old patient presents for evaluation of right nipple discomfort. The patient has family history of a mother and sister with premenopausal breast cancer.

Clinical History

A 57-year-old patient presents for evaluation of right nipple discomfort. The patient has family history of a mother and sister with premenopausal breast cancer.

Findings

Digital mammography shows area of calcifications (Figure 1a-b). Magnification views demonstrate intraductal pleomorphic microcalcifications in the right 11:00 area (Figure 1c).

No noted findings on physical exam or ultrasound.

Diagnosis

Vacuum assisted stereotactic needle core biopsy of the right breast 11:00 microcalcifications reveals ductal carcinoma in situ.

MRI imaging performed for extent of disease demonstrates linear beaded enhancement extending from nipple posteriorly for 8cm within the right breast upper outer quadrant (Figure 2a-b).
 

Discussion

This case demonstrates the benefit of multimodality imaging including digital mammography and breast magnetic resonance imaging (MRI) in this patient, which led to a diagnosis of ductal carcinoma in situ (DCIS). There has been some conflicting information in the literature regarding MRI and its usefulness in the evaluation of DCIS. For this patient, the MRI revealed the extensive area of involvement more so than mammography. This information was critical to the surgeon for surgical planning.

This article was originally published at Diagnostic Imaging

Recent Videos
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.